Experimental Drug Shrinks Some Lung Tumors in Early Trial

Adults with lung cancer that stopped responding to immunotherapy saw tumors shrink in a third of patients given the highest tested dose in an early study.

Updated on Nov. 6, 2026 in Cancer

Single clear glass vessel of pale amber liquid on a brushed-steel laboratory bench under soft directional light.
OncoC4 reported early trial results showing its experimental drug cesalatamig shrank lung tumors in a third of heavily pretreated patients at the highest tested dose. AI Illustration. Upload story photo >

OncoC4 reported Phase 1/2 results for its drug cesalatamig given alone to previously treated non-small cell lung cancer (NSCLC) patients. Among 55 efficacy-evaluable patients who had progressed on PD-(L)1 therapy, the 10 mg/kg every-three-weeks dose produced a 33% objective response rate, and the findings will be presented at SITC 2026 in Phoenix.

Why it matters

For adults with NSCLC whose cancer has stopped responding to immunotherapy and chemotherapy, few options remain, so an early signal of tumor shrinkage in a heavily pretreated group is notable. These are early, single-arm trial results in a small number of patients, so they indicate a direction for further study rather than a proven treatment benefit.

This pooled analysis of Phase 1/2 studies enrolled 103 NSCLC patients who received at least one dose, with 55 evaluable for efficacy. The trials were global, multicenter, and open-label, meaning there was no comparison group and results are preliminary.

The players

OncoC4

A Rockville, Maryland-based biopharmaceutical company developing cancer immunotherapies, including cesalatamig.

U.S. Food and Drug Administration (FDA)

The U.S. agency that regulates drugs and granted cesalatamig Fast Track designation to speed review of treatments for serious conditions.

Society for Immunotherapy of Cancer (SITC)

A professional society whose 2026 Annual Meeting in Phoenix will host the late-breaking presentation of the cesalatamig results.

The details

Cesalatamig is designed to engage two targets at once, linking immune cells to cancer cells so the immune system can attack tumors more effectively. Patients received the drug at 1, 3, 10 or 20 mg/kg every three weeks, and the drug was well tolerated across all dose levels. Most participants had already received multiple prior lines of treatment, with a median of two and 42% having three or more.

Timeline

  1. September 2026: The U.S. FDA granted cesalatamig Fast Track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.

  2. November 6, 2026: OncoC4 publicly reported the Phase 1/2 results.

  3. November 7, 2026: The results will be presented in a late-breaking oral presentation at SITC 2026 in Phoenix.

Health Landscape

Bispecific T-cell engager antibodies, a drug class that links immune cells to tumor cells, are being tested as an approach for lung cancer that has stopped responding to immunotherapy. Early single-arm data like these help show whether the approach is worth advancing to larger randomized trials.

If you or a family member has NSCLC that has progressed on immunotherapy, this early research may be worth discussing with your oncologist as a sign of where trials are heading. Clinical trial participation is a conversation to have with your treating physician, since these results are preliminary and come from a small group of patients.

The takeaway

Early trial data suggest cesalatamig may shrink tumors in some heavily pretreated lung cancer patients, but these results are preliminary and drawn from a small group. Anyone exploring treatment options should ask their oncologist about current clinical trials for NSCLC that has progressed after immunotherapy.

What happens next

A late-breaking oral presentation of the full results is scheduled for November 7, 2026, at the SITC 2026 Annual Meeting in Phoenix, and the 10 mg/kg dose is planned for a pivotal study.

Further reading

For broader background on how these therapies are being developed, see the Cancer section.